Abstract:Abstract Background: Alzheimer’s disease (AD) is a leading cause of dementia in the elderly and has become a major health issue. However, a large number of genetic risk factors remain undiscovered. Methods: To identify novel risk genes and better understand the molecular pathway underlying AD, whole-exome sequencing (WES) was performed in 215 early-onset AD (EOAD) patients and 55 unrelated healthy controls of Han Chinese ethnicity. Subsequent direct sequencing was performed in 4962 individuals to validate the selected rare mutations. Computational annotation and in vitro functional studies were performed to evaluate the role of candidate mutations in EOAD and the underlying mechanisms.Results: We identified two rare missense mutations in the phosphodiesterase 11A (PDE11A) gene, resulting in p.Arg202His, and p.Leu756Gln, in individuals with EOAD. Both mutations are located in evolutionarily highly conserved amino acids, are predicted to alter the protein conformation, and classified as pathogenic. Furthermore, we found significantly decreased protein levels of PDE11A in brain samples of AD patients. Expression of PDE11A variants and knockdown experiments with specific short hairpin RNA (shRNA) for PDE11A both resulted in an increase of AD-associated Tau hyperphosphorylation at T181, S404, S202, S416, S214, S396 and AT8 epitopes in vitro. PDE11A variants or PDE11A shRNA also caused increased cAMP levels, protein kinase A (PKA) activation, and cAMP response element-binding protein (CREB) phosphorylation. Additionally, pretreatment with a PKA inhibitor (H89) suppressed PDE11A mutation-induced p-Tau formation.Conclusions: Our results demonstrate that both PDE11A mutations and PDE11A knockdown increase Tau phosphorylation through the cAMP/PKA pathway, suggesting that PDE11A is a novel risk gene for AD. This study provides insight into the involvement of Tau phosphorylation via the cAMP/PKA pathway in EOAD pathogenesis and provides a potential new target for intervention.

Exome Sequencing Revealed PDE11A as a Novel Candidate Gene for Early-Onset Alzheimer's disease

Two Novel Pde11a Genetic Variants Increase Tau Phosphorylations in Early-onset Alzheimer's Disease

Genetic Analysis of PICK1 Gene in Alzheimer's Disease: A Study for Finding a New Gene Target

Targeted sequencing on neurodegenerative genes identified novel causal and risk variants of familial Alzheimer's disease

Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing

Two Novel Mutations and a De Novo Mutation in PSEN1 in Early-onset Alzheimer’s Disease

P3‐120: MOLECULAR GENETIC ANALYSIS OF APP, PSEN1, AND PSEN2 GENES IN CHINESE PATIENTS WITH ALZHEIMER'S DISEASE

A Pathogenic Variant p.Phe177Val in PSEN1 Causes Early-Onset Alzheimer’s Disease in a Chinese Family

Neprilysin Confers Genetic Susceptibility to Alzheimer’s Disease in Han Chinese

A Novel AβPP M722K Mutation Affects Amyloid-β Secretion and Tau Phosphorylation and May Cause Early-Onset Familial Alzheimer's Disease in Chinese Individuals.

A Novel PSEN1 K311R Mutation Discovered in Chinese Families with Late-Onset Alzheimer's Disease Affects Amyloid-β Production and Tau Phosphorylation.

Clinical and genetic characteristics in a central-southern Chinese cohort of early-onset Alzheimer's disease

Identification of Alzheimer's disease-associated rare coding variants in the ECE2 gene.

Whole Exome Sequencing Analyses Identified Novel Genes for Alzheimer's Disease and Related Dementia

Identification of a Novel PSEN1 Gly111Val Missense Mutation in a Chinese Pedigree with Early-Onset Alzheimer's Disease

Identification of a Rare <i>PSEN1</i> Mutation (Thr119Ile) in Late-Onset Alzheimer's Disease With Early Presentation of Behavioral Disturbance

is a novel risk gene for Alzheimer's disease in Han Chinese.

Association of Rare Variants in Neurodegenerative Genes with Familial Alzheimer's Disease.

Exome sequence analysis of rare frequency variants in Late-Onset Alzheimer Disease

Mutation Screening in Chinese Patients with Familial Alzheimer's Disease by Whole-Exome Sequencing.

De novo deleterious genetic variations target a biological network centered on Aβ peptide in early-onset Alzheimer disease